# SPECIALTY GUIDELINE MANAGEMENT

# **ALUNBRIG** (brigatinib)

#### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### A. FDA-Approved Indication

Alunbrig is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

### B. Compendial Uses

- 1. Recurrent, advanced or metastatic ALK rearrangement-positive NSCLC as a single agent
- 2. Brain metastases from ALK rearrangement-positive NSCLC as a single agent
- 3. Inflammatory myofibroblastic tumor (IMT) with ALK translocation as a single agent

All other indications are considered experimental/investigational and not medically necessary.

#### **II. DOCUMENTATION**

Submission of the following information is necessary to initiate the prior authorization review: ALK mutation status

#### III. CRITERIA FOR INITIAL APPROVAL

### A. Non-Small Cell Lung Cancer (NSCLC)

Authorization of 12 months may be granted for treatment of recurrent, advanced, or metastatic ALK-positive NSCLC (including brain metastases from NSCLC) as a single agent.

## B. Inflammatory Myofibroblastic Tumor (IMT)

Authorization of 12 months may be granted for treatment of ALK-positive IMT as a single agent.

#### IV. CONTINUATION OF THERAPY

#### A. Non-Small Cell Lung Cancer (NSCLC)

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity while on the current regimen.

## B. Inflammatory Myofibroblastic Tumor (IMT)

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Alunbrig 1815-A SGM P2021.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s) 1815-A

## V. REFERENCES

- 1. Alunbrig [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; May 2020.
- 2. The NCCN Drugs & Biologics Compendium® © 2021 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed February 22, 2021.

Alunbrig 1815-A SGM P2021.docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

